Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track VALN with free AI briefings, catalyst countdowns, and dilution alerts.

VALN · Valneva SE

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$121.5M Cash on Hand
26.2mo Cash Runway
Follow VALN by email Get an email when VALN reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about VALN, unsubscribe in one click. Privacy

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
VIMKUNYA Chikungunya Virus Infection Phase 4 · NCT06928753 Recruiting
IXIARO®- Japanese Encephalitis vaccine Japanese Encephalitis Vaccine Phase 4 · NCT03971058 Unknown
IXCHIQ Chikungunya Virus Infection Phase 4 · NCT06928753 Recruiting
Active Chikungunya Phase 3 · NCT04650399 Completed
VLA2001 - adolescent SARS-CoV-2 Virus Infection Phase 3 · NCT04864561 Completed
VLA2001 SARS-CoV-2 Virus Infection Phase 3 · NCT04956224 Completed
VLA1553 Chikungunya Virus Infection Phase 3 · NCT04838444 Active not recruiting
VLA15 Lyme Disease Phase 3 · NCT05477524 Completed
Pneumococcal 7-Valent Conjugate Vaccine Encephalitis Phase 3 · NCT01041573 Completed
JE-VAX Japanese Encephalitis Phase 3 · NCT00604708 Completed
Japanese Encephalitis purified inactivated… Japanese Encephalitis Phase 3 · NCT00605085 Completed
Japanese Encephalitis Virus Strain SA 14-14-2… Japanese Encephalitis Phase 3 · NCT01296360 Completed
IC51 Japanese Encephalitis Encephalitis Phase 3 · NCT01041573 Completed
IC51 has given in the parent study IC51-322 Japanese Encephalitis Phase 3 · NCT01246479 Completed
IC51 Japanese Encephalitis Phase 3 · NCT00594958 Completed
Active Comparator: 6.0mg GRI-0621 SARS-CoV-2 Infection Phase 2/3 · NCT05298644 Withdrawn

Also used in these trials (approved or third-party drugs, not VALN's own candidates): Alum.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

VALN holds $121.5M in cash and short-term investments and burns about $13.9M/quarter from operations, an estimated runway of 26.2 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 25 · Moderate

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when VALN files for a raise →

👥 Who Owns VALN

Insiders Form 4 data not loaded yet Other 5%+ holders 11% Institutions (23 holders) 4% Public and other holders 85%
HolderTypeShares% of sharesAs of
Caisse des depots et consignations 5%+ holder (13D) 19,074,653 10.99% 2026-05-05

Share count 173,539,745 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full VALN picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for VALN and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.